Laurie Frakes

Hematology | Oncology
16918 Dove Canyon Rd Ste 103
San Diego, CA 92127

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 1 publications

A phase II study of afatinib (BIBW 2992), an irreversible ErbB family blocker, in patients with HER2-positive metastatic breast cancer progressing after trastuzumab.

A phase II study of afatinib (BIBW 2992), an irreversible ErbB family blocker, in patients with HER2-positive metastatic breast cancer progressing after trastuzumab.

Journal: Breast cancer research and treatment
Published: February 15, 2012
Showing 1-1 of 1

Last Updated: 09/26/2026